LEXXW - DehydraTECH(TM) - Enabled Consumer Products Now Available in Over 7000 Stores
(TheNewswire)
Lexaria’s technology empowersbrands nationwide in stores including Albertsons, Hudson News, andmany more
Kelowna, British Columbia - TheNewswire – July 28, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the“Company” or “Lexaria”), a global innovator in drug deliveryplatforms is pleased to announce that its DehydraTECH TM technology hasbeen embraced by consumer brands now available for sale in over 7,000stores across the US.
“Lexaria’s technology is enabling increased marketshare and sales growth for our continually growing list of corporateclients,” said Chris Bunka, CEO of Lexaria. “We are delighted tohelp these innovators of today and leaders of tomorrow offer theirclients superior performance and experiences that competitors simplycannot match, and we are highly anticipatory of additional growth tocome.”
Lexaria asked several of its corporate clients to sharetheir experiences with DehydraTECH:
Case Mandal, President of Cannadips, said, “Cannadipsis the original tobacco-free and nicotine-free CBD pouch and we prideour Humboldt County traditions of innovation and continualtechnological evolution to help consumers nationwide enjoy superiordip experiences. We scoured the market for the best technology to putinto our products and DehydraTECH was, hands down, the most palatableand efficacious delivery system for our CBD products. Cannadips CBDpouches are available nationwide in 5,500 stores, and online at www.cannadipscbd.com . ”
Brent Mann, Founder and President of New World CBD,offered that “New World CBD is family owned and operated and isstriving to become the best CBD company in America. Our diverse CBDproducts are sold now in over 1,500 Albertsons, Safeway, and Vonsstores, and in more than 300 Hudson News locations, and we are indiscussions to have our products sold in another 96,000 convenienceand grocery stores nationwide. All of our next-generation topicalproducts – five new SKUs expected in Q4 2021 - will be usingLexaria’s DehydraTECH technology; we chose the best for our productlines. Our products are also available at www.newworldcbd.com . ”
Vassili Kotlova, President of Impact Naturals said that“Impact Naturals is a science- and health-focused group with decadesof biotech and pharmaceutical experience where our R&D seeks tounlock the full potential of natural compounds to benefit human healthand wellness. We chose to use DehydraTECH as the basis of ournext-generation CHYLOSOMA™ formulations of CBD, CBG and CBN alongwith American Ginseng, Ginkgo Biloba and Melatonin. We will also beintroducing 3 topical skin SKUs empowered with DehydraTECH during Q4,2021. All our products can be purchased at www.impact-naturals.com . ”
Eric Gricus, CEO and Founder of Amari, commented,“ Amari went through an extensive selectionprocess for our CBD technology supplier. Lexaria exceeded ourexpectations for product quality, service and pricing. DehydraTECH’s fast onset, high bioavailability and watersolubility is the perfect complement to our proprietary blends ofturmeric, ashwagandha and plant-based ingredients designed to helppeople Play Longer and Recover Faster. We arethrilled to have the Lexaria team working with Amari to provide products our customers love while winning industry accolades. Our products can bepurchased at retailers across the country and at www.amaribotanicals.com .”
Lexaria only partners with the most advanced thinking,forward looking brands in America and is delighted to be experiencingincreases in market share and growth with these and our numerous otherB2B clients this year that it believes will continue to flourish intothe future. The companies above do not represent a complete list ofLexaria’s B2B clients and we will introduce more of these industryleaders at a future date.
All of Lexaria’s B2B clients share at least one vitalattribute; that their customers are the most important part of theirbusinesses and delivering “average” consumer experiences is simplynot good enough. Lexaria and our B2B partners expect our consumers todemand the best, and this is what we deliver, each and every day.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. Since 2016, DehydraTECH has repeatedly demonstrated theability to increase bio-absorption withcannabinoids and nicotine by up to 5-10x, reducetime of onset from 1 - 2 hours to minutes, and mask unwanted tastes;and is planned to be further evaluated for orally administeredbioactive molecules, including anti-viral drugs, vitamins,non-steroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria haslicensed DehydraTECH to multiple companies including a world-leadingtobacco producer for the development of smokeless, oral-based nicotineproducts and for use in industries that produce cannabinoid beverages,edibles, and oral products. Lexaria operates a licensed in-houseresearch laboratory and holds a robust intellectual property portfoliowith 21 patents granted and over 50 patents pending worldwide. Formore information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances or otherwise, exceptas otherwise required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.